

Yinghong Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4860548/publications.pdf>

Version: 2024-02-01

65
papers

8,064
citations

361296

20
h-index

214721

47
g-index

67
all docs

67
docs citations

67
times ranked

7348
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1714-1768.	0.8	2,691
2	Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. , 2017, 5, 95.		1,460
3	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4126.	0.8	580
4	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. <i>Nature Medicine</i> , 2018, 24, 1804-1808.	15.2	521
5	Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1695-1705.	0.9	177
6	Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. , 2018, 6, 37.		174
7	Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. , 2018, 6, 142.		146
8	Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. , 2018, 6, 95.		146
9	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2738-2745.	0.8	138
10	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	0.8	135
11	Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. , 2019, 7, 93.		131
12	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. , 2018, 6, 103.		130
13	Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. <i>Annals of Oncology</i> , 2020, 31, 724-744.	0.6	129
14	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 387-405.	2.3	124
15	AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. <i>Gastroenterology</i> , 2021, 160, 1384-1393.	0.6	121
16	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 3978-3992.	0.8	121
17	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. , 2020, 8, e000604.		98
18	Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. , 2019, 7, 31.		94

#	ARTICLE	IF	CITATIONS
19	Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?. Inflammatory Bowel Diseases, 2019, 25, 385-393.	0.9	63
20	Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. , 2019, 7, 242.		60
21	Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunology, Immunotherapy, 2019, 68, 553-561.	2.0	57
22	Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors. New England Journal of Medicine, 2021, 384, 581-583.	13.9	53
23	Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scandinavian Journal of Gastroenterology, 2019, 54, 538-545.	0.6	51
24	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. , 2021, 9, e003277.		49
25	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers, 2020, 12, 1862.	1.7	47
26	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
27	Immune Checkpoint Inhibitorâ€“Mediated Diarrhea and Colitis: A Clinical Review. JCO Oncology Practice, 2020, 16, 453-461.	1.4	42
28	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. European Journal of Cancer, 2021, 157, 140-152.	1.3	42
29	The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patientsâ€™ Outcomes. Journal of Immunotherapy and Precision Oncology, 2018, 1, 7-18.	0.6	40
30	Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. , 2021, 9, e002058.		30
31	Systematic review with metaâ€“analysis: effectiveness of antiâ€“inflammatory therapy in immune checkpoint inhibitorâ€“induced enterocolitis. Alimentary Pharmacology and Therapeutics, 2020, 52, 1432-1452.	1.9	28
32	Immune Checkpoint Inhibitors-Induced Hepatitis. Advances in Experimental Medicine and Biology, 2018, 995, 159-164.	0.8	26
33	Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. , 2019, 7, 118.		26
34	Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. , 2019, 7, 47.		22
35	Immune-checkpoint inhibitors induced diarrhea and colitis. Current Opinion in Gastroenterology, 2020, 36, 25-32.	1.0	21
36	Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726.		21

#	ARTICLE	IF	CITATIONS
37	Immune Checkpoint Inhibitors-Induced Colitis. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 151-157.	0.8	19
38	Clinical Features of Rituximab-associated Gastrointestinal Toxicities. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 539-545.	0.6	19
39	Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 700-708.	2.3	19
40	Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 662-668.	0.9	18
41	Clinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients. <i>Current Gastroenterology Reports</i> , 2019, 21, 8.	1.1	17
42	Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 797-799.	1.1	13
43	Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 789-796.	0.6	12
44	Clinical characteristics of colitis induced by taxane-based chemotherapy. <i>Annals of Gastroenterology</i> , 2019, 33, 59-67.	0.4	12
45	Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1415-1424.	2.3	10
46	Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 402-408.	0.6	7
47	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. <i>Hepatology Communications</i> , 2022, 6, 1776-1785.	2.0	7
48	Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1251-1259.	1.9	6
49	Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. <i>Clinical Colorectal Cancer</i> , 2020, 19, e117-e123.	1.0	6
50	Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent <i>Clostridioides difficile</i> in cancer patients. <i>Journal of Cancer</i> , 2021, 12, 6498-6506.	1.2	6
51	Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 40-45.	0.6	6
52	Severe fistulizing pancreatitis in a patient with Merkel cell carcinoma treated with avelumab. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1266-1267.	0.8	5
53	Gastrointestinal Tract Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 247-253.	0.8	5
54	Management of Immune-Related Colitis During the COVID-19 Pandemic. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e110-e111.	0.9	4

#	ARTICLE	IF	CITATIONS
55	An Aggressive Approach Toward a Case of Refractory Ulcerative Colitis With Uncertain Etiology in the Context of Chronic Myeloid Leukemia. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e26-e27.	0.9	4
56	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1128-1155.	1.1	4
57	Hepatobiliary Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 271-276.	0.8	3
58	Rate of colorectal neoplasia in patients with Hodgkin lymphoma. <i>Colorectal Disease</i> , 2020, 22, 154-160.	0.7	2
59	Checkpoint Inhibitor-Induced Colitis. <i>American Journal of Gastroenterology</i> , 2020, 115, 1301-1302.	0.2	2
60	Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 0, , .	1.4	2
61	Patients with Non-Hodgkin's Lymphoma Are at Risk of Adenomatous Colon Polyps. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2965-2971.	1.1	1
62	Reply to Y. Inagaki et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 1749-1750.	0.8	1
63	Patients with non-colorectal cancers may be at elevated risk of colorectal neoplasia. <i>Journal of Cancer</i> , 2020, 11, 3192-3198.	1.2	0
64	Efficacy and Safety of Vedolizumab and Infliximab Treatment for Immune-Mediated Diarrhea and Colitis in Cancer Patients: A Multi-Center Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
65	Immunotherapy-Mediated Luminal Gastrointestinal Toxicities. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 331-337.	0.8	0